The ALK gene rearrangement is observed in 3–5% of adenocarcinomas of the lung [2,3], and, hence, identifying patients with ALK aberrations who might benefit from the kinase inhibitor treatment is critical for effective NSCLC treatment. This evidence concerns the gene ALK and non-small cell lung carcinoma.